Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Baxter
Medtronic
Colorcon
McKinsey

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Custirsen

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Custirsen?

Custirsen is an investigational drug.

There have been 12 clinical trials for Custirsen. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Lung Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are OncoGenex Technologies, NCIC Clinical Trials Group, and Teva Pharmaceutical Industries.

There are two US patents protecting this investigational drug and thirty-five international patents.

Recent Clinical Trials for Custirsen
TitleSponsorPhase
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationTeva Pharmaceutical IndustriesPhase 1
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationOncoGenex TechnologiesPhase 1
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerOncoGenex TechnologiesPhase 3

See all Custirsen clinical trials

Clinical Trial Summary for Custirsen

Top disease conditions for Custirsen
Top clinical trial sponsors for Custirsen

See all Custirsen clinical trials

US Patents for Custirsen

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Custirsen   Start Trial Ester derivatives of androgen receptor modulators and methods for their use The University of British Columbia (Vancouver, BC, CA) British Columbia Cancer Agency Branch (Vancouver, BC, CA)   Start Trial
Custirsen   Start Trial Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer The University of British Columbia (Vancouver, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Custirsen

Drugname Country Document Number Estimated Expiration Related US Patent
Custirsen Australia 2014262333 2033-05-10   Start Trial
Custirsen Australia 2016228233 2033-05-10   Start Trial
Custirsen Brazil 112015028174 2033-05-10   Start Trial
Custirsen Canada 2911352 2033-05-10   Start Trial
Custirsen Chile 2015003271 2033-05-10   Start Trial
Custirsen China 105358522 2033-05-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
Moodys
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.